Adjuvants and Vector Systems for Allergy Vaccines

作者：Moingeon Philippe^*; Lombardi Vincent; Saint Lu Nathalie; Tourdot Sophie; Bodo Veronique; Mascarell Laurent

来源：Immunology and Allergy Clinics of North America, 2011, 31(2): 407-+.

DOI：10.1016/j.iac.2011.03.001

• Adjuvants
• Allergy vaccine
• Immunopotentiation
• Immunotherapy
• Mucosal immunity
• Vector system

Allergen-specific immunotherapy represents a curative treatment of type I allergies. Subcutaneous immunotherapy is conducted with allergens adsorbed on aluminum hydroxide or calcium phosphate particles, whereas sublingual immunotherapy relies on high doses of soluble allergen without any immunopotentiator. There is a potential benefit of adjuvants enhancing regulatory and Thl CD4+T cell responses during specific immunotherapy. Molecules affecting dendritic cells favor the induction of T regulatory cell and Thl responses and represent valid candidate adjuvants for allergy vaccines. Furthermore, the interest in viruslike particles and mucoadhesive particulate vector systems, which may better address the allergen(s) to tolerogenic antigen-presenting cells, is documented.

• 出版日期2011-5